FXR an emerging therapeutic target for the treatment of atherosclerosis

Atherosclerosis is the leading cause of illness and death. Therapeutic strategies aimed at reducing cholesterol plasma levels have shown efficacy in either reducing progression of atherosclerotic plaques and atherosclerosis-related mortality. The farnesoid-X-receptor (FXR) is a member of metabolic n...

Descripción completa

Detalles Bibliográficos
Autores principales: Mencarelli, Andrea, Fiorucci, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2010
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837604/
https://www.ncbi.nlm.nih.gov/pubmed/20041971
http://dx.doi.org/10.1111/j.1582-4934.2009.00997.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837604/
https://www.ncbi.nlm.nih.gov/pubmed/20041971
http://dx.doi.org/10.1111/j.1582-4934.2009.00997.x

Ejemplares similares